Web9 mrt. 2024 · Inxmed Co. Ltd. has raised $50 million in a series B round to support clinical trials of its lead candidate, IN-10018, for the treatment of multiple cancers in both the … Web18 okt. 2024 · InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting drug resistance for hard-to-treat solid tumors, …
InxMed FAK Inhibitor IN10018 Received Breakthrough Therapy …
Web1 jun. 2013 · Windson Organics Private Limited. Aug 2014 - Apr 20247 years 9 months. India. • Define and execute strategy to drive business in profitable international channels … WebInxMed General Information. Description. Developer of cancer therapeutics. The company currently has pharmaceuticals targeting pancreatic, ovarian, gastric and other forms of … lists crossword clue
Refreshgene Therapeutics VentureRadar
Web20 dec. 2024 · 这是应世生物首个获得NMPA临床试验许可的创新药物,此前IN10018已于2024年8月30日获得美国FDA临床试验许可。. 应世生物创始人兼CEO王在琪博士表 … Web8 sep. 2024 · InxMed Co., Ltd, a clinical-stage biotechnology company dedicates to developing innovative therapies targeting drug resistance and metastasis for hard-to … WebPrivate. InxMed is a clinical-stage biotech company established in the end of 2024. The company dedicates on developing innovative therapies targeting stroma … impacted ear wax drops